LAG 525

Drug Profile

LAG 525

Alternative Names: Anti-LAG-3-monoclonal-antibody - Novartis Oncology; LAG525

Latest Information Update: 07 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Developer Novartis Oncology
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD223 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 13 Dec 2017 Novartis plans a phase II trial for Solid tumours and Diffuse large B-cell lymphoma (Late stage disease, Second-line therapy, Combination therapy), in December 2017 (NCT03365791)
  • 10 Jun 2015 Preclinical trials in Solid tumours in Switzerland (unspecified route)
  • 10 Jun 2015 Novartis plans a phase Ib/II trial for Solid tumours (Late-stage disease) in USA, Australia, Canada and Singapore (NCT02460224)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top